November 18th 2024
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
September 27th 2024
Residual Cardiovascular Risks: Don’t Forget Kidney and Vascular Disease
February 28th 2013Typical interventions in persons without CKD are essential. SHARP and TNT have added to our knowledge. Aggressive cholesterol lowering (probably also affecting LDL particle number as well as traditional measures of LDL) seems to afford better outcomes by lessening residual risk in those with chronic kidney disease.
Medical News You May Have Missed (Week of Jan. 14)
January 16th 2013The FDA requires reductions in recommended doses of zolpidem; update on the flu; new BP goals for patients with diabetes; selective use of D-Dimer for suspected DVT; new food safety standards. . . here: 5 quick summaries of medical news headlines with links out to original sources.
New Spin on Hypertension: Sequelae of Excess Glucocorticoids and Mineralocorticoids
August 28th 2012Persons with primary hyperaldosteronism and hypertension are at significantly increased risk for cardiovascular morbidity and mortality. But if these patients are treated with spironolactone and reach target blood pressure, their CV outcomes are the same as those of others with essential hypertension after 6.5 years of follow-up.